



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/803,653	03/12/2001	Winfried Siffert	741135-12	6614

22204 7590 09/20/2002
NIXON PEABODY, LLP
8180 GREENSBORO DRIVE
SUITE 800
MCLEAN, VA 22102

[REDACTED] EXAMINER

MYERS, CARLA J

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1634

DATE MAILED: 09/20/2002

b

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/803,653	SIFFERT, WINFRIED
Examiner	Art Unit	
Carla Myers	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-40 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

- 5) Claim(s) _____ is/are allowed.

- 6) Claim(s) _____ is/are rejected.

- 7) Claim(s) _____ is/are objected to.

- 8) Claim(s) 1-40

are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.

- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ . | 6) <input type="checkbox"/> Other: _____ . |

Art Unit: 1634

RESTRICTION

1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1, 28, 31-32 and 39, drawn to nucleic acids, classified in Class 536, subclass 23.5.

II. Claims 2-17, drawn to methods to detect nucleic acids, classified in Class 435, subclass 6.

III. Claims 18-27, drawn to methods for evaluating in vivo therapy, classified in Class 435, subclass 6.

IV. Claim 29, drawn to a method of using Gbeta3 protein to identify inhibitors, classified in Class 435, subclass 7.1

V. Claim 30, drawn to a Gbeta3 protein, classified in Class 530, subclass 350.

VI. Claims 33-36, drawn to methods of expressing a protein by introducing a nucleic acid into a cell, classified in Class 514, subclass 44.

VII. Claim 37, drawn to the use of a nucleic acid for producing a pharmaceutical, classified in Class 514, subclass 44.

VIII. Claim 38, drawn to a transgenic animal, classified in Class 800, subclass 8.

IX. Claim 40, drawn to antibodies, classified in Class 530, subclass 387.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II and I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for

Art Unit: 1634

using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the nucleic acids of invention I can be used in a materially different process, such as for synthesizing nucleic acids or proteins.

Inventions I and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the nucleic acids of invention I are not required to practice the method of invention IV.

Inventions I and V are patentably distinct in structure and physicochemical properties. Invention I is drawn to nucleic acids whereas invention V is drawn to proteins. Because nucleic acids are composed of nucleotides and proteins are composed of amino acids, the inventions have different structural and functional properties. Furthermore, the products are utilized in different methodologies, such that nucleic acids may be utilized in hybridization assays, while proteins may be utilized in ligand binding assays or to generate antibodies. Synthesis of the proteins of invention V do not require the particular products of the nucleic acids of invention I since the proteins of invention V can be isolated from natural sources or chemically synthesized.

Inventions I and VI and I and VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that

Art Unit: 1634

product (M.P.E.P. § 806.05(h)). In the instant case, the nucleic acids of invention I can be used in a materially different process, such as for diagnostic purposes.

Inventions I and VIII are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the transgenic animal is a patentably distinct entity over the nucleic acids since the transgenic animal has its own unique functional and structural characteristics. The subcombination has separate utility such as to serve as a template for DNA or RNA synthesis or as a probe in a hybridization assay.

Inventions I and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the nucleic acids of invention I are not required to make the antibodies of invention IX. Furthermore, the different inventions are not disclosed as capable of use together and have different functions and have different physical and structural properties.

Inventions II, III, IV, VI, and VII are unrelated to each other. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

Art Unit: 1634

In the instant case, the different inventions have different objectives, involve performing different method steps and require the use of different reagents. Inventions II, III, IV, VI and VII are novel and unobvious over each other.

Inventions II and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the proteins of invention V are not required to practice the methods of inventions II.

Inventions II and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the transgenic animals of invention VIII are not required to practice the method of invention II.

Inventions II and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the antibodies of invention IX are not required to practice the method of invention II.

Inventions III and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different

Art Unit: 1634

functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the proteins of invention V are not required to practice the methods of inventions III.

Inventions III and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the transgenic animals of invention VIII are not required to practice the method of invention III.

Inventions III and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the antibodies of invention IX are not required to practice the method of invention III.

Inventions IV and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the proteins of invention V can be used in a materially different process, such as for generating antibodies or for therapeutic purposes.

Inventions IV and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation,

Art Unit: 1634

different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the transgenic animals of invention VIII are not required to practice the method of invention IV.

Inventions IV and IX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the antibodies of invention IX can be used in a materially different process, such as for therapeutic purposes.

Inventions V and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions have different physical and functional properties and are novel and unobvious over each other.

Inventions V and IX are patentably distinct in structure in that the proteins of invention III have a different amino acid sequence as compared to the antibodies of invention IV. Furthermore, the products of invention III and IV are utilized in different methodologies, such that the proteins may be utilized in ligand binding assays and the antibodies may be used in therapeutic methods. Synthesis of the antibodies of invention IV does not require the particular

Art Unit: 1634

products of the proteins of invention III since the antibodies of invention IV can be isolated from natural sources.

Inventions VI and VIII and VII and VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the transgenic animals of invention VIII are not required to practice the methods of invention VI or VII.

Inventions VI and IX and VII and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the antibodies of invention IX are not required to practice the methods of invention VI or VII.

Inventions VIII and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are not disclosed as capable of use together because the antibodies of invention IX are not required to make the transgenic animal of invention VIII and the antibodies of invention IX have unique structural and functional properties distinct from the transgenic animals of invention VIII.

Art Unit: 1634

2. Because these inventions are distinct for the reasons given above and have acquired a different status in the art as demonstrated by their different classification and recognized divergent subject matter and because inventions I-IX require different searches that are not co-extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.

3. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is (703) 308-2199. The examiner can normally be reached on Monday-Thursday from 6:30 AM-5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703)-308-1152. The fax number for the Technology Center is (703)-305-3014 or (703)-305-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the receptionist whose telephone number is (703) 308-0196.

Carla Myers

Carla Myers
CARLA J. MYERS
PRIMARY EXAMINER

September 19, 2002